Skip to main content
Premium Trial:

Request an Annual Quote

Delfi Diagnostics FirstLook Lung Test

Delfi Diagnostics has launched the FirstLook Lung blood-based test for detecting lung cancer using low-dose CT. The test, which has a negative predictive value of 99.7 percent, leverages fragmentomics to discover cancer cells that are more chaotic than normal cells and leave tell-tale patterns and characteristics of cell-free DNA in the blood when they die. It applies machine learning to whole-genome sequencing data to compare a patient's cDNA patterns and characteristics with individuals with and without cancer to identify those who may have lung cancer, including early-stage cancer.